About 2nd Inflammasome Therapeutics Summit

Built with Inflammasome Therapeutics, GSK, and Novartis, the 2nd Inflammasome Therapeutics Summit is the only industry focused meeting dedicated to solving the challenges of targeting the inflammasome to develop clinically effective therapeutics. Bringing together over 200 of the industry’s leading experts to one virtual meeting, this event will gather pharma, biotech and academia to overcome the challenges and opportunities the inflammasome field is facing.

This year’s summit will once again unite thought leaders in inflammasome drug development to discuss clinical developments in 2019/2020, share novel inflammatory pathways outside of NLRP3, the development of the NLRP3 pathway and translate these into clinically effective therapeutics.

The Inflammasome Therapeutics Summit is the industry’s definitive inflammasome drug development conference. Dedicated to overcoming challenges in developing clinically effective inflammasome therapeutics, this comprehensive discussion and networking forum will enable you to:

• Optimize your clinical trial design and hear the latest readouts from the clinic
• Deepen your biological understanding of how the inflammasome is activated and regulated at a cellular level
• Identify novel inflammasome pathways focussing not only on NLRP-3 but looking beyond and outside of this exciting pathway
• Determine which diseases the inflammasome is driving and therefore which have the most therapeutic potential commercially and clinically

Across two parallel tracks of learning and 31 speakers, don’t miss this unique opportunity to be part of the online discussion. Sharing hotly anticipated case studies and lessons learned exclusively focused on the discovery and translational challenges, we bring you the leading and unmissable Inflammasome Therapeutics Summit.